COMMUNICATION
Topoisomerase II-mediated DNA Cleavage and Religation in the Absence of Base Pairing
ABASIC LESIONS AS A TOOL TO DISSECT ENZYME MECHANISM*

Paul S. KingmaDagger and Neil OsheroffDagger §

From the Departments of Dagger  Biochemistry and § Medicine (Oncology), Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0146

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

The interaction of topoisomerase II with its DNA cleavage site is critical to the physiological functions of the enzyme. Despite this importance, the specific enzyme-DNA interactions that drive topoisomerase II-mediated DNA cleavage and religation are poorly understood. Therefore, to dissect interactions between the enzyme and its cleavage site, abasic DNA lesions were incorporated into a bilaterally symmetrical and identical cleavage site. Results indicate that topoisomerase II has unique interactions with each position of the 4-base overhang generated by enzyme-mediated DNA cleavage. Lesions located 2 bases 3' to the point of scission stimulated cleavage the most, whereas those 3 bases from the point of scission stimulated cleavage the least. Moreover, an additive and in some cases synergistic cleavage enhancement was observed in oligonucleotides that contained multiple DNA lesions, with levels reaching >60-fold higher than the wild-type substrate. Finally, topoisomerase II efficiently cleaved and religated a DNA substrate in which apyrimidinic sites were simultaneously incorporated at every position on one strand of the 4-base overhang. Therefore, unlike classical DNA ligases in which base pairing is the driving force behind closure of the DNA break, it appears that for topoisomerase II, the enzyme is responsible for the spatial orientation of the DNA termini for ligation.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Eukaryotic topoisomerase II is an enzyme that is required for a number of indispensable nuclear processes, including DNA replication, recombination, and chromosome segregation (1-4). Moreover, it is the primary target for some of the most effective and commonly employed anticancer chemotherapy regimens used for the treatment of human malignancies (5-9). However, in order for topoisomerase II to fulfill its pivotal role in any of these processes, it must create double-stranded breaks in the genetic material.

Topoisomerase II generates these breaks by the concerted actions of two active site tyrosyl residues, each of which induces a transient, single-stranded nick in opposite strands of the DNA helix, such that a 4-base 5'-overhang is generated (10, 11). The integrity of the genetic material is preserved during the cleavage reaction by the formation of covalent phosphotyrosyl bonds between these residues and the newly generated 5' termini (12). Following ATP binding, a second helix is translocated through the topoisomerase II-associated double-stranded DNA break, and the cleaved DNA is religated (13-15).

Despite the importance of the DNA cleavage/religation reaction to the functions of topoisomerase II, relatively little is known regarding the specific enzyme-DNA interactions that drive this reaction. Although consensus DNA cleavage sequences have been reported for the eukaryotic enzyme, they are relatively weak and show little similarity to one another (8, 16). Thus, the molecular interactions that underlie the site specificity of topoisomerase II remain an enigma.

Previous attempts to dissect interactions between the enzyme and its cleavage site characterized the effects of DNA lesions (apurinic sites, apyrimidinic sites, or base mismatches) incorporated at specific positions in a topoisomerase II cleavage site (17-20). All of these lesions displayed a strict positional specificity. When they were located within the 4-base overhang generated by cleavage, levels of DNA scission increased ~3-18-fold. Conversely, lesions located immediately outside the 4-base overhang inhibited DNA cleavage. Although position-specific variations in stimulatory DNA lesions were observed, conclusions regarding nucleotide positions within the 4-base overhang were limited because the relative effects of position (e.g. removal of a base at the point of scission versus one base away) as opposed to sequence (e.g. removal of a guanine versus an adenine) could not be distinguished.

To bypass these limitations and more fully define interactions between the enzyme and specific positions within its DNA cleavage site, abasic sites were incorporated into a topoisomerase II cleavage site in which the central bases were bilaterally symmetrical and identical (see Fig. 1). Because abasic lesions contained within a given strand of this cleavage site differed only by location rather than the type of base removed, this site allowed a systematic analysis of the 4-base overhang in topoisomerase II-mediated DNA cleavage/religation. Results indicate that topoisomerase II displays a positional preference, such that the efficacy of DNA lesions is dependent on their location within the cleavage site. In addition, the enzyme efficiently cleaves and religates a DNA substrate in which apyrimidinic sites are simultaneously incorporated at every position on one strand of the 4-base overhang, demonstrating that base pairing within the cleavage site is not required either for formation or closure of the DNA break.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Preparation of Oligonucleotides-- A 40-base single-stranded oligonucleotide that corresponds to residues 1072-1111 of the MLL oncogene (21, 22) and its complementary oligonucleotide were prepared by Cruachem Inc. The sequences of the top and bottom oligonucleotides were 5'-GCCTGGGTGACAAAGCdown-arrow AAAACACTGTCTCCAAAAAAAATT-3' and 5'-AATTTTTTTTGGAGACAGTGdown-arrow TTTTGCTTTGTCACCCAGGC-3', respectively. The points of topoisomerase II-mediated DNA cleavage are denoted by the arrows. Single-stranded oligonucleotides containing a tetrahydrofuran abasic site analogue were prepared in a similar manner utilizing a tetrahydrofuran phosphoramidite. Single-stranded oligonucleotides were labeled on their 5' termini with [32P]phosphate, purified by polyacrylamide gel electrophoresis, and annealed as described previously (18).

Topoisomerase II-mediated DNA Cleavage-- Topoisomerase II-mediated DNA cleavage reactions were carried out by a protocol similar to that of Kingma et al. (19). Reactions contained 100 nM oligonucleotide in 19 µl of cleavage buffer (10 mM Tris-HCl, pH 7.9, 0.1 mM EDTA, 100 mM KCl, and 2.5% glycerol) that contained 5 mM MgCl2 and were initiated by the addition of 1 µl of human topoisomerase IIalpha (final concentration, 150 nM). (Human topoisomerase IIalpha was purified from Saccharomyces cerevisiae as described previously (19).) Reactions were incubated for 10 min at 37 °C and stopped with 2 µl of 10% SDS followed by 1.5 µl of 250 mM EDTA. When appropriate, cleavage reactions were reversed by the addition of 1.5 µl of 250 mM EDTA for 5 min at 37 °C prior to the detergent. Cleavage products were digested with proteinase K, precipitated twice with ethanol, and resolved by electrophoresis in denaturing 7 M urea, 14% polyacrylamide gels as described previously (18). Reaction products were visualized and quantified using a PhosphorImager system. In all cases (other than those that incorporated an abasic site on both strands), cleavage was monitored on the complementary wild-type strand. Levels of DNA cleavage were calculated either relative to that obtained with the wild-type substrate or from the percentage of total substrate that was cleaved.

Topoisomerase II-mediated DNA Religation-- DNA religation assays were carried out by a modification of the procedure of Osheroff and Zechiedrich (23). Cleavage/religation equilibria were established as described above in cleavage buffer that contained 5 mM CaCl2. Kinetically competent topoisomerase II-DNA cleavage complexes were trapped by the addition of EDTA (final concentration, 6 mM). NaCl was added (final concentration, 500 mM) to prevent recleavage. Religation was initiated by the addition of MgCl2 (final concentration, 0.1 mM) and terminated by the addition of 2 µl of 10% SDS at various times up to 60 s. Samples were prepared and analyzed as described above. The apparent first order rate of DNA religation was determined by quantifying the loss of the cleavage product.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

To dissect the recognition of the DNA cleavage site by topoisomerase II and the role of base pairing in the cleavage/religation reaction of the enzyme, abasic lesions were incorporated into a 40-base pair oligonucleotide that corresponds to residues 1072-1111 of the MLL gene and includes a topoisomerase II cleavage site at nucleotide position 1087 (21, 22). This bilaterally symmetrical site was utilized because it contains identical bases along each strand of the 4-base overhang (i.e. all adenine residues on the top strand and thymine residues on the bottom) (Fig. 1). The positions of DNA lesions are designated relative to the point of cleavage with the points of scission on both the top and bottom strands located 5' to the +1 base. Cleavage of the top and bottom strands of this 5'-labeled oligonucleotide by human topoisomerase IIalpha results in the formation of radioactive 16- and 20-base products, respectively, such that a 4-base 5'-cleavage overhang is generated.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 1.   Positional preference of topoisomerase II-mediated DNA cleavage. Reactions contained wild-type oligonucleotide (None) (shown at top) or wild-type oligonucleotide annealed to a complementary oligonucleotide that contained an apurinic (Top) or apyrimidinic (Bottom) site at the indicated positions. Levels of DNA cleavage were determined as the percentage of the total substrate cleaved. Data represent the averages of three independent experiments. Standard deviations are indicated by error bars.

Topoisomerase II Displays a Positional Preference for DNA Lesions in the 4-base Overhang-- The sensitivity of human topoisomerase IIalpha toward alterations at specific positions in the 4-base cleavage overhang was characterized by incorporating abasic DNA lesions at each position within the top and bottom strands (Fig. 1). Consistent with our previous work (17, 19), each individual lesion stimulated enzyme-mediated DNA cleavage, and greater levels of cleavage were observed with apurinic sites (top strand) than with apyrimidinic sites (bottom strand). However, levels of cleavage stimulation for either type of lesion were not uniform across the cleavage site. Consistently, lesions at the +2 position stimulated DNA scission the most, ~9-11-fold above the wild-type substrate. In contrast to the strong preference for the +2 position, only a weak preference (~2-3-fold above wild-type) for the +3 position was detected on both strands. The preference for lesions placed at the +1 versus +4 positions was irregular. When comparing these two positions, a slight preference for the +1 position was observed on the top strand, whereas on the bottom strand the +4 position was preferred. As discussed below, these findings suggest a predisposition of the enzyme for the "left side" of the cleavage site.

Although the cleavage site utilized in this study permits a unique analysis of the positional preferences of the enzyme, the generality of these conclusions must be tempered by the fact that only a single site was examined. However, these preferences are supported by results obtained with at least two other DNA cleavage sites (19).1 Even with the above caveat, it is clear that topoisomerase II does not have uniform interactions with each base of the overhang; rather the enzyme appears to have a positional preference for DNA lesions and displays specific responses to alterations at each position.

Multiple Abasic DNA Lesions Stimulate Topoisomerase II-mediated DNA Cleavage-- Several clinically relevant anticancer drugs exert their chemotherapeutic actions by increasing levels of covalent topoisomerase II-cleaved DNA complexes (6-9). As a result of their actions, drugs that "poison" topoisomerase II (i.e. shift the cleavage/religation equilibrium toward the cleaved state) increase levels of protein-associated DNA breaks and are lethal to rapidly dividing cancer cells. The original models proposed for the actions of these poisons generally placed a drug molecule at the point of scission on each strand of the double helix with two molecules acting in concert to stimulate double-stranded DNA cleavage (6, 8, 16, 24-26).

Based on the results of previous studies with DNA lesions, an alternative model known as the "positional poison model" was proposed that encompassed the actions of both anticancer drugs and DNA lesions (18). Unlike previous drug models, the positional poison model suggested that two drug molecules were not required to stimulate double-stranded DNA cleavage, because a single, strand-specific DNA lesion was capable of enhancing enzyme-mediated DNA cleavage at both points of scission. Therefore, to extend our use of DNA lesions as a probe of drug mechanism, a series of oligonucleotides containing two abasic sites was analyzed to determine whether multiple lesions might also display a positional preference.

In most cases, the stimulatory effects of multiple DNA lesions appeared to be at least additive (i.e. levels of cleavage with two DNA lesions were as high as the theoretical sum of cleavage levels observed with the individual abasic sites) (Fig. 2, compare closed and open bars). This additive effect was observed when abasic sites were positioned adjacent to each other (17), separated by a gap, or located at both points of scission in either the +1 top/+1 bottom or the +4 top/+4 bottom positions (the postulated locations of drugs (6, 8, 16, 24-26)). Therefore, although only one topoisomerase II poison is required to induce double-stranded DNA cleavage, two appear to produce greater levels of cleavage enhancement.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 2.   Topoisomerase II-mediated DNA cleavage in the presence of two DNA lesions. DNA cleavage reactions were carried out in the presence of double-stranded wild-type oligonucleotide (shown at top) or oligonucleotide that contained abasic sites at the indicated positions on the Top, Bottom, or Both strands. DNA scission was monitored on the complementary wild-type strand. For substrates with DNA lesions on both the top (T) and bottom (B) strands, DNA scission was monitored on the bottom strand. In all cases, levels of cleavage (closed bars) were calculated relative to the wild-type substrate. The theoretical sum of DNA cleavage levels for the individual lesions are shown (open bars). Data represent the averages of three independent experiments. Standard deviations are indicated by error bars.

Remarkably, in some cases a synergistic effect was observed. When lesions were incorporated at the +1/+2 or the +2/+3 positions on the top strand or the +2/+3 or the +3/+4 positions on the bottom strand levels of cleavage stimulation reached >60-fold and were ~2-3-fold greater than the predicted additive effects of the individual DNA lesions. Because this superadditive effect was only observed with abasic lesions at these positions, it appears that synergism within this cleavage site is dependent on two primary factors. First, the abasic sites must be located adjacent to each other. Second, lesions must be positioned on the left side of the cleavage site, such that the +1 or +2 positions on the top strand or the +3 or +4 positions on the bottom strand are included.

Topoisomerase II-mediated DNA Cleavage and Religation in the Absence of Base Pairing-- Previous work by Westergaard and co-workers examined the importance of base pairing in ligation reactions between a topoisomerase II-cleaved DNA complex and external, acceptor fragments of DNA (27). In this intermolecular ligation reaction, base pairing of the external fragment to the cleaved DNA was important for the positioning of the incoming termini and enhanced rates of ligation as much as 8-fold. In contrast, studies that incorporated single abasic sites or base mismatches within a topoisomerase II cleavage site indicated that intramolecular DNA religation mediated by the enzyme (i.e. resealing the original DNA break covalently linked to topoisomerase II) was not inhibited by disruption of one of the 4 base pairs within the overhang (17, 18). Therefore, to further define the importance of base pairing within the 4-base overhang, enzyme-mediated DNA cleavage and intramolecular religation were examined in the presence of multiple abasic sites.

As seen in Fig. 3, topoisomerase II tolerated the removal of all four pyrimidines on the bottom strand (apyrimidinic sites were used because they are less disruptive to the structure of the double helix than apurinic sites (28-30)). In fact, cleavage increased significantly with the removal of each successive base and reached levels >60-fold above the wild-type substrate when all 4 bases on the bottom strand were removed.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 3.   Topoisomerase II-mediated DNA cleavage and religation in the absence of base pairing. DNA cleavage reactions contained wild-type substrate (None) or oligonucleotides with apyrimidinic sites located at the indicated positions. Cleavage was stopped by the addition of SDS (closed bars) or reversed by treatment with EDTA (hatched bars) prior to detergent. Results from an additional reaction carried out in the presence of ATP (ATP) are shown. Data represent the averages of three independent experiments. Standard deviations are indicated by error bars.

Despite these dramatic increases in DNA scission, >= 90% of the cleavage was reversed by the addition of EDTA, even when all the base pairing was removed from the 4-base overhang (Fig. 3). In addition, under conditions in which the enzyme was capable of carrying out DNA strand passage (i.e. in the presence of ATP), cleavage was still reversible in the absence of base pairing. Therefore, base pairing within the overhang is not required for either DNA cleavage or religation mediated by topoisomerase II.

Although not necessary for religation, the potential contributions of base pairing to the rate of this reaction are unknown. Therefore, the kinetics of religation were examined using a series of apyrimidinic substrates (Fig. 4). Removal of one (+1 position) or two bases (either at the +1/+2 or +3/+4 positions) from the bottom strand did not inhibit rates of religation. In fact, rates appeared to increase slightly, which is consistent with earlier findings with single DNA lesions (17). Removal of 3 or 4 bases decreased rates of religation ~2-3-fold, a relatively minor effect when compared with the >60-fold stimulation of cleavage induced by four apyrimidinic sites. It is unclear whether this small decrease in the rate of religation reflects a minor contribution of base pairing to this reaction or whether it reflects a lesion-induced structural distortion of the cleavage site in addition to the potential effects of base pairing. This notwithstanding, it is clear that under the conditions used in this system, base pairing is not the driving force behind topoisomerase II-mediated DNA religation.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 4.   Rates of topoisomerase II-mediated DNA religation in the absence of base pairing. DNA religation was carried out in the presence of wild-type oligonucleotide (open circle ) or oligonucleotide containing apyrimidinic sites at the +1 (bullet ), +1+2 (square ), +3+4 (black-triangle), +1+2+3 (black-square), or +1+2+3+4 (triangle ) positions. At time 0, levels of DNA cleavage for each oligonucleotide were set to 100%. The apparent first order rates of religation were determined by monitoring the loss of the cleavage product. Data represent the averages of two independent experiments.

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Determining the specific molecular interactions that govern the topoisomerase II-mediated DNA cleavage/religation reaction is vital to our understanding of this essential enzyme. In this study, abasic DNA lesions were used to reveal some of the critical features of this reaction.

Results indicate that topoisomerase II has a positional preference for DNA lesions located within the 4-base cleavage overhang. Although every DNA lesion introduced within this region stimulated DNA scission, levels of cleavage with abasic sites at the +2 position were consistently the highest, and those at the +3 position were the lowest. Moreover, an additive and in some cases synergistic effect was observed in oligonucleotides that contained more than one abasic site. Considering the dramatic cleavage stimulation (>60-fold above wild-type) observed with certain combinations of DNA lesions, it is tempting to speculate that the efficacy of anticancer drugs might be substantially improved if they were capable of distorting multiple base pairs within the 4-base overhang. Finally, two lines of evidence suggest that the interactions between topoisomerase II and this DNA cleavage sequence are biased toward the left side of this site. First, cleavage levels observed with single DNA lesions at the +1 top or +4 bottom positions on the left side of the cleavage site were ~2-fold higher than levels observed with lesions at the +4 top or +1 bottom positions, respectively, on the right side. Second, the synergistic effects of multiple abasic sites were only detected with adjacent DNA lesions that included at least one of the two positions on the left side of the cleavage site. Because the leftward bias was observed in independent experiments that examined either apurinic or apyrimidinic sites, it does not appear to be specific to the type of lesion utilized. Beyond this observation, the specific molecular interactions that underlie the leftward bias of this cleavage site are unclear. However, the homodimeric structure of the enzyme and the symmetrical nature of the central bases of this site suggest that this bias must originate from the nonsymmetrical region immediately outside the 4-base overhang.

Although removing the bases from the cleavage overhang significantly stimulates the DNA scission reaction of topoisomerase II, base pairing in this region is not required for religation of the break and in relative terms has only a minor effect on the reaction rate. This is in marked contrast to most classical DNA ligases, which are dramatically inhibited by the loss of base pairing within their substrate. How does topoisomerase II religate a cleaved DNA substrate in the absence of base pairing? The defining property that distinguishes topoisomerase II from DNA ligases is its covalent linkage to the DNA strands containing the unpaired bases. This may explain why DNA termini covalently linked to topoisomerase II can be positioned and religated correctly by the enzyme without the assistance of base pairing. Thus, the driving force behind topoisomerase II-mediated DNA religation appears to be conformational changes within the enzyme rather than complementarity between the cohesive ends.

Finally, this work may address how some topoisomerase II poisons can stimulate DNA cleavage without inhibiting DNA religation (5, 7). Although topoisomerase II preferentially recognizes and cleaves the double helix when it is distorted by a drug molecule or DNA lesion (as suggested in the positional poison model (18)), religation of the single-stranded DNA termini apparently is orchestrated primarily by the enzyme independent of the DNA structure. Thus, the same distortion of the double helix that alters the forward DNA cleavage reaction would have no effect on the reversal of this process.

In summary, the interaction of topoisomerase II with its DNA cleavage site is critical to the physiological and therapeutic functions of the enzyme. DNA lesions are rapidly becoming a powerful tool for understanding the factors that dictate these interactions.

    ACKNOWLEDGEMENTS

We are grateful to P. B. Kingma, Dr. D. Andrew Burden, S. D. Cline, J. M. Fortune, and M. Sabourin for critical reading of the manuscript.

    FOOTNOTES

* This work was supported by Grants GM33944 and GM53960 from the National Institutes of Health.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Dept. of Biochemistry, 654 Medical Research Bldg. I, Vanderbilt University School of Medicine, Nashville, TN 37232-0146. Tel.: 615-322-4338; Fax: 615-343-1166; E-mail: osheron{at}ctrvax.vanderbilt.edu.

1 S. D. Cline and N. Osheroff, unpublished results.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Cozzarelli, N. R., and Wang, J. C. (1990) DNA Topology and Its Biological Effects, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
  2. Osheroff, N., Zechiedrich, E. L., and Gale, K. C. (1991) BioEssays 13, 269-273[Medline] [Order article via Infotrieve]
  3. Watt, P. M., and Hickson, I. D. (1994) Biochem. J. 303, 681-695[Medline] [Order article via Infotrieve]
  4. Wang, J. C. (1996) Annu. Rev. Biochem. 65, 635-692[CrossRef][Medline] [Order article via Infotrieve]
  5. Corbett, A. H., and Osheroff, N. (1993) Chem. Res. Toxicol. 6, 585-597[Medline] [Order article via Infotrieve]
  6. Chen, A. Y., and Liu, L. F. (1994) Annu. Rev. Pharmacol. Toxicol. 34, 191-218[CrossRef][Medline] [Order article via Infotrieve]
  7. Froelich-Ammon, S. J., and Osheroff, N. (1995) J. Biol. Chem. 270, 21429-21432[Free Full Text]
  8. Pommier, Y., Fesen, M. R., and Goldwasser, F. (1996) in Cancer Chemotherapy and Biotherapy: Principles and Practice (Chabner, B. A., and Longo, D. L., eds), 2nd Ed., pp. 435-461, Lippincott-Raven Publishers, Philadelphia, PA
  9. Nitiss, J. L., and Beck, W. T. (1996) Eur. J. Cancer 32a, 958-966[CrossRef]
  10. Liu, L. F., Rowe, T. C., Yang, L., Tewey, K. M., and Chen, G. L. (1983) J. Biol. Chem. 258, 15365-15370[Abstract/Free Full Text]
  11. Sander, M., and Hsieh, T. (1983) J. Biol. Chem. 258, 8421-8428[Abstract/Free Full Text]
  12. Rowe, T. C., Chen, G. L., Hsiang, Y. H., and Liu, L. F. (1986) Cancer Res. 46, 2021-2026[Abstract]
  13. Osheroff, N., Shelton, E. R., and Brutlag, D. L. (1983) J. Biol. Chem. 258, 9536-9543[Abstract/Free Full Text]
  14. Osheroff, N. (1987) Biochemistry 26, 6402-6406[Medline] [Order article via Infotrieve]
  15. Robinson, M. J., and Osheroff, N. (1991) Biochemistry 30, 1807-1813[Medline] [Order article via Infotrieve]
  16. Capranico, G., and Zunino, F. (1992) Eur. J. Cancer 12, 2055-2060
  17. Kingma, P. S., and Osheroff, N. (1997) J. Biol. Chem. 272, 7488-7493[Abstract/Free Full Text]
  18. Kingma, P. S., and Osheroff, N. (1997) J. Biol. Chem. 272, 1148-1155[Abstract/Free Full Text]
  19. Kingma, P. S., Greider, C. A., and Osheroff, N. (1997) Biochemistry 36, 5934-5939[CrossRef][Medline] [Order article via Infotrieve]
  20. Bigioni, M., Zunino, F., Tinelli, S., Austin, C. A., Willmore, E., and Capranico, G. (1996) Biochemistry 35, 153-159[CrossRef][Medline] [Order article via Infotrieve]
  21. Felix, C. A., Lange, B. J., Hosler, M. R., Fertala, J., and Bjornsti, M. (1995) Cancer Res. 55, 4287-4292[Abstract]
  22. Gu, Y., Alder, H., Nakamura, T., Schichman, S. A., Prasad, R., Canaani, O., Saito, H., Croce, C. M., and Canaani, E. (1994) Cancer Res. 54, 2326-2330[Abstract]
  23. Osheroff, N., and Zechiedrich, E. L. (1987) Biochemistry 26, 4303-4309[Medline] [Order article via Infotrieve]
  24. Capranico, G., Kohn, K. W., and Pommier, Y. (1990) Nucleic Acids Res. 18, 6611-6619[Abstract]
  25. Freudenreich, C. H., and Kreuzer, K. N. (1993) EMBO J. 12, 2085-2097[Abstract]
  26. Freudenreich, C. H., and Kreuzer, K. N. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 11007-11011[Abstract/Free Full Text]
  27. Schmidt, V. K., Sorensen, B. S., Sorensen, H. V., Alsner, J., and Westergaard, O. (1994) J. Mol. Biol. 241, 18-25[CrossRef][Medline] [Order article via Infotrieve]
  28. Raap, J., Dreef, C. E., van der Marel, G. A., van Boom, J. H., and Hilbers, C. W. (1987) J. Biomol. Struct. Dyn. 5, 219-247[Medline] [Order article via Infotrieve]
  29. Singh, M. P., Hill, G. C., Peoc'h, D., Rayner, B., Imbach, J. L., and Lown, J. W. (1994) Biochemistry 33, 10271-10285[Medline] [Order article via Infotrieve]
  30. Vesnaver, G., Chang, C. N., Eisenberg, M., Grollman, A. P., and Breslauer, K. J. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 3614-3618[Abstract]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.